Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of 6-month sustained-release triptorelin in prostate cancer
2006-007055-41Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Mar 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triptorelin in prostate cancer (PCa), sponsored by Ipsen. Primary endpoints: Pharmacodynamic profile based on testosterone serum levels and Proportion achieving medical castration at Day 31. Started Mar 2007; status: terminated.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-007055-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007055-41.